Bulimia Nervosa Treatment Market, by Treatment Type (Drug Treatment (Selective Serotonin Reuptake Inhibitor, Serotonin-Norepinephrine Reuptake Inhibitor, Benzodiazepines, Tricyclic Antidepressants, and Others) and Non-drug Treatment (Nutritional Therapy,

Bulimia Nervosa Treatment Market, by Treatment Type (Drug Treatment (Selective Serotonin Reuptake Inhibitor, Serotonin-Norepinephrine Reuptake Inhibitor, Benzodiazepines, Tricyclic Antidepressants, and Others) and Non-drug Treatment (Nutritional Therapy, Behavioral Therapy, and Others)), by Route of Administration (Oral, Intravenous, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Bulimia nervosa is a type of eating disorder, in which the person eat large amount of food (binge eating) within a short period of time, after which the person tends to lose weight by two ways: purging and non-purging. Purging includes vomiting post eating and non-purging includes fasting, enemas, use of laxatives and diuretics, and excessive exercising. Bulimia nervosa may lead to various life-threatening complications such as tooth & gum decay, heart problems, self-injury, dehydration, and digestive problems.
Market Dynamics
Research institutes are indulged in launching websites, in order to spread awareness about the latest eating disorders treatment options, among the population, which is expected to fuel growth of the market over the forecast period. For instance, in 2018, ECRI institute, a non-profit organization, launched a bulimia nervosa guide website for the patients and their caretakers. This website provide guidelines and latest information about the treatment options for the bulimia nervosa.
Research institutes are indulged in conducting clinical trials for finding the effectiveness of behavioral therapy for the treatment of eating disorders. For instance, on 7th November 2020, National Institute of Mental Health (NIMH) announced that, they are recruiting adult women patients suffering from bulimia nervosa for conducting clinical trials, in order to determine the effectiveness of cognitive behavioral therapy in the treatment of bulimia nervosa.
Key features of the study:
This report provides an in-depth analysis of global bulimia nervosa treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global bulimia nervosa treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global bulimia nervosa treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the bulimia nervosa treatment market
Detailed Segmentation:
Global Bulimia Nervosa Treatment Market, By Treatment Type:
Drug Treatment
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Benzodiazepines
Tricyclic Antidepressants
Others
Non-drug Treatment
Nutritional Therapy
Behavioral Therapy
Others
Global Bulimia Nervosa Treatment Market, By Route of Administration:
Oral
Intravenous
Others
Global Bulimia Nervosa Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Bulimia Nervosa Treatment Market, By Region:
North America
By Country
U.S.
Canada
By Treatment Type:
Drug Treatment
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Benzodiazepines
Tricyclic Antidepressants
Others
Non-Drug Treatment
Nutritional Therapy
Behavioral Therapy
Others
By Route of Administration
Oral
Intravenous
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Treatment Type:
Drug Treatment
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Benzodiazepines
Tricyclic Antidepressants
Others
Non-Drug Treatment
Nutritional Therapy
Behavioral Therapy
Others
By Route of Administration
Oral
Intravenous
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Treatment Type:
Drug Treatment
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Benzodiazepines
Tricyclic Antidepressants
Others
Non-Drug Treatment
Nutritional Therapy
Behavioral Therapy
Others
By Route of Administration
Oral
Intravenous
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Treatment Type:
Drug Treatment
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Benzodiazepines
Tricyclic Antidepressants
Others
Non-Drug Treatment
Nutritional Therapy
Behavioral Therapy
Others
By Route of Administration
Oral
Intravenous
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Treatment Type:
Drug Treatment
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Benzodiazepines
Tricyclic Antidepressants
Others
Non-Drug Treatment
Nutritional Therapy
Behavioral Therapy
Others
By Route of Administration
Oral
Intravenous
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Treatment Type:
Drug Treatment
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Benzodiazepines
Tricyclic Antidepressants
Others
Non-Drug Treatment
Nutritional Therapy
Behavioral Therapy
Others
By Route of Administration
Oral
Intravenous
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Allergan, Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Eli Lilly and Company
AstraZeneca plc
Alembic Pharmaceuticals Ltd
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Pfizer Inc.
Johnson & Johnson Services, Inc.
Dr. Reddy’s Laboratories Limited
Lupin Pharmaceuticals, Inc.
Aurobindo Pharma
Zydus Cadila
Apotex Inc.
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
“*” marked represents similar segmentation in other categories in the respective section.